Literature DB >> 15296340

Reactive type II pneumocytes in bronchoalveolar lavage fluid.

Kitty C F M Linssen1, Jan A Jacobs, Venerino E Poletti, Walther van Mook, Elisa I M Cornelissen, Marjolein Drent.   

Abstract

OBJECTIVE: To evaluate the prevalence of reactive type II pneumocytes (RPII) in bronchoalveolar lavage (BAL) fluid samples obtained from patients with various pulmonary disorders. STUDY
DESIGN: Consecutive BAL fluid samples were screened for the presence of RPII on May-Grünwald-Giemsa-stained cytocentrifuge preparations. BAL fluid samples with and without RPII were compared with regard to prevalence, associated clinical diagnoses and cytologic findings.
RESULTS: RPII were generally large cells with a high nuclear:cytoplasmic ratio and deeply blue-stained, vacuolated cytoplasm. Most RPII occurred in cohesive cell groups, and the vacuoles tended to be confluent. Cytologic findings associated with RPII were foamy alveolar macrophages, activated lymphocytes and plasma cells. RPII were present in 94 (21.7%) of 433 included BAL fluid samples. The highest prevalences were noted in patients with systemic inflammatory response syndrome and alveolar hemorrhage. In addition, RPII tended to occur more frequently in ventilator-associated pneumonia, Pneumocystis carinii pneumonia, extrinsic allergic alveolitis and drug-induced pulmonary disorders. In contrast, RPII were not observed in BAL fluid samples obtained from patients with sarcoidosis.
CONCLUSION: RPII were prevalent in about 20% of BAL fluid specimens. They were associated mainly with conditions of acute lung injury and not observed in sarcoidosis.

Entities:  

Mesh:

Year:  2004        PMID: 15296340     DOI: 10.1159/000326411

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  7 in total

1.  Variant VKORC1 and CYP2C9 alleles in patients with diffuse alveolar hemorrhage caused by oral anticoagulants.

Authors:  Petal A Wijnen; Catharina F Linssen; Guido R Haenen; Otto Bekers; Marjolein Drent
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

2.  Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients.

Authors:  Catharina F M Linssen; Jan A Jacobs; Foekje F Stelma; Walther N K A van Mook; Peter Terporten; Cornelis Vink; Marjolein Drent; Cathrien A Bruggeman; Annick Smismans
Journal:  Intensive Care Med       Date:  2008-08-05       Impact factor: 17.440

3.  Bronchoalveolar lavage cytological alveolar damage in patients with severe pneumonia.

Authors:  Bogdan Grigoriu; Frédéric Jacobs; Fabienne Beuzen; Rony El Khoury; Olivier Axler; Francois G Brivet; Frédérique Capron
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

4.  Clinical course and complications following diagnostic bronchoalveolar lavage in critically ill mechanically ventilated patients.

Authors:  R M Schnabel; K van der Velden; A Osinski; G Rohde; P M H J Roekaerts; D C J J Bergmans
Journal:  BMC Pulm Med       Date:  2015-09-29       Impact factor: 3.317

5.  Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study.

Authors:  Maxens Decavèle; Antoine Parrot; Michaël Duruisseaux; Martine Antoine; Anne Fajac; Audrey Milon; Marie-France Carette; Anthony Canellas; Aude Gibelin; Alexandre Elabbadi; Marie Wislez; Jacques Cadranel; Muriel Fartoukh
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

6.  Seasonal variation of serum KL-6 concentrations is greater in patients with hypersensitivity pneumonitis.

Authors:  Hiroshi Ohnishi; Shintaro Miyamoto; Shigeo Kawase; Tetsuya Kubota; Akihito Yokoyama
Journal:  BMC Pulm Med       Date:  2014-08-07       Impact factor: 3.317

7.  Mimivirus is not a frequent cause of ventilator-associated pneumonia in critically ill patients.

Authors:  M J Vanspauwen; R M Schnabel; C A Bruggeman; M Drent; W N K A van Mook; D C J J Bergmans; C F M Linssen
Journal:  J Med Virol       Date:  2013-07-16       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.